Medical technology company Odinwell reduced its operating loss in the second quarter while revenue declined, and the company aims to begin launching the veterinary product novaQS during the fourth quarter. Revenue amounted to SEK 0.7 million (1.0), a decrease of 27.7 percent compared with the previous year. Revenue consisted of capitalised development costs and product sales revenue. Operating profit was SEK -1.4 million (-1.7). Net profit amounted to SEK -1.4 million (-1.7). Earnings per share were SEK -0.03 (-0.04). "It has been an eventful quarter with several important milestones. Particularly encouraging is that we have now taken a first step towards commercialisation through the sale of two novaQS systems to the Swedish University of Agricultural Sciences (SLU) for research and education. The sale is clear evidence that the veterinary medicine product has reached a level of maturity that enables us to move into the next phase of our journey. SLU is a leading institution in Swedish veterinary medicine, and the fact that they are showing such great interest in our product gives us confidence that we have developed the right product. Thus, the development of the veterinary segment has grown into a strong part of our product portfolio, and we see that we will soon be launching our product on the market," writes CEO Marcus Andersson. Cash and cash equivalents amounted to SEK 1.4 million (5.5) at the end of the quarter. During the quarter, a directed share issue of approximately SEK 3.3 million was carried out, the proceeds from which are reported in the third quarter. Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeRevenue0.71.0-27.7%Operating profit-1.4-1.7-Net profit-1.4-1.7-Earnings per share, SEK-0.03-0.04-Cash and cash equivalents1.45.5-74.1%